本季度信息
截至2026年3月31日，华润医药实现营收10.36亿元，同比下降12.50%。同期经调整净利润为3.12亿元，同比上升1.71%。报告期内，公司现金及现金等价物净增加额约为1.19亿元，高于上一年同期的0.47亿元。期末现金及现金等价物余额约为8.28亿元，去年同期为6.99亿元。
截至2026年3月31日，公司总资产71.60亿元，总负债21.39亿元，所有者权益50.21亿元，较2025年年底均有一定幅度提升。
本季度信息
截至2026年3月31日，华润医药实现营收10.36亿元，同比下降12.50%。同期经调整净利润为3.12亿元，同比上升1.71%。报告期内，公司现金及现金等价物净增加额约为1.19亿元，高于上一年同期的0.47亿元。期末现金及现金等价物余额约为8.28亿元，去年同期为6.99亿元。
截至2026年3月31日，公司总资产71.60亿元，总负债21.39亿元，所有者权益50.21亿元，较2025年年底均有一定幅度提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.